| Source:
A new formulation and presentation of Depo-Provera® will soon become available, offering the potential to create access for new users while improving continuation among existing users. This new version, known as depo-subQ provera 104™ in the Uniject®* device (depo-subQ in Uniject), contains 104 mg of depot medroxyprogesterone acetate (DMPA) and is administered via subcutaneous injection. The Uniject delivery system is a small, autodisable injection device that is prefilled with the precise dosage of depo-subQ required for three months of contraceptive protection. Introduction of depo-subQ in Uniject provides opportunities to both strengthen clinic injection services and extend injectable contraceptive delivery safely and effectively beyond the clinic.
- Regions/Countries:
- Global |
- Global
WHO Upholds Guidance: Women With or at Risk of HIV Can Safely Use Hormonal Methods
WHO released a statement on February 16, 2012, upholding guidance indicating that women with HIV or at high risk of HIV can safely use hormonal contraceptives, including injectables, to prevent pregnancy. However, WHO is instructing health care providers to strongly advise such women who decide to use progestin-only injectables to also always use male or female condoms for protection against HIV. Read more about WHO's statement.
The information provided on this website is not official U.S. Government information and does not represent the views or position
of the U.S. Agency for International Development, the U.S. Government, or The Johns Hopkins University. Read our full Security & Privacy Policies.